A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

被引：1
|
作者：
Gasparetto, Cristina [1 ]
Green, Michael [2 ]
Srinivasan, Anandgopal [3 ]
Kang, Yubin [4 ]
Rizzieri, David A. [2 ]
Decastro, Carlos [1 ]
Diehl, Louis F. [1 ]
Beaven, Anne [1 ]
Li, Zighuo [1 ]
Rao, Arati V. [5 ,6 ]
Garrett, Anderson [1 ]
Tuchman, Sascha [7 ]
Long, Gwynn D. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27710 USA
[3] Univ Cambridge, Sch Clin Med, Cambridge, England
[4] Duke Univ, Med, Durham, NC USA
[5] Duke Univ, Div Cellular Therapy, Med, Durham, NC USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Duke Univ, Durham, NC USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.1857.1857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Victoria Mateos, Maria
    Prosper, Felipe
    Martin Sanchez, Jesus
    Ocio, Enrique M.
    Oriol, Albert
    Motllo, Cristina
    Michot, Jean-Marie
    Jarque, Isidro
    Iglesias, Rebeca
    Sole, Maria
    Martinez, Sara
    Kahatt, Carmen
    Fudio, Salvador
    Corral, Gema
    Zeaiter, Ali
    Montilla, Lola
    Ribrag, Vincent
    CANCER MEDICINE, 2023, 12 (04): : 3999 - 4009
  • [42] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
  • [43] Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.
    Chari, A
    Kaplan, L
    Linker, C
    Damon, LE
    Navarro, WH
    Martin, T
    BLOOD, 2005, 106 (11) : 379B - 379B
  • [44] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
  • [45] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Shalaby, Khalid
    Carlson, Louise
    Celotto, Kimberly
    Chavel, Colin
    Lund, Ian
    McCaffrey, Kristina
    Schaefer, Megan
    Dupuis, Megan
    Hillengass, Jens
    Lee, Kelvin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma
    Manasanch, Elisabet E.
    Jain, Preetesh
    Chen, Wendy
    Oriabure, Onyeka
    Badillo, Maria
    Feng, Lei
    Berkova, Zuzana
    Orlowski, Robert Z.
    Wang, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (09) : E232 - E235
  • [48] Lenalidomide in combination with Bendamustine and Prednisolone (RBP) in patients with refractory or relapsed multiple myeloma. Preliminary results of a phase I clinical trial
    Poenisch, W.
    Heyn, S.
    Wagner, I
    Mohren, M.
    Hoffmann, F. A.
    Schueler, F.
    Al-Ali, H. K.
    Jaekel, N.
    Niederwieser, D.
    ONKOLOGIE, 2010, 33 : 156 - 156
  • [49] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Ball, Edward D.
    Larson, Sarah M.
    Sirianni, Lindsey
    Mulroney, Carolyn M.
    Costello, Caitlin L.
    BLOOD, 2023, 142
  • [50] A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Hari, Parameswaran
    Schroeder, Mark A.
    Berenson, James R.
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Voorhees, Peter M.
    Fujii, Hisaki
    Yang, Zhao
    Galimi, Francesco
    Shain, Kenneth H.
    BLOOD, 2018, 132
12345